Comparison of the Immunogenicity and Safety of Two Pediatric TBE Vaccines Based on the Far Eastern and European Virus Subtypes

Table 4

Immunogenicity of Tick-E-Vac and FSME-IMMUN Junior.

Schedule	Vaccine	Tick-E-Vac				FSME-IMMUN Junior
	Blood sampling	N	SRs, %	GMTA, log10		N	SRs, %	GMTA, log10
				Total	Only seropositive			Total	Only seropositive
CS	30 days after administration of the second dose	49	100	2.5	2.5	42	95.2	2.4	2.5
				M = 2.5 (1.0–3.3)	M = 2.5 (1.0–3.3)			M = 2.4 (0–3.3)	M = 2.5 (1.1–3.3)
RS	14 days after administration of the second dose	27	63	1.0^a	1.6^b	28	50	0.9^c	1.8^d
				M = 1.2 (0–3.3)	M = 1.4 (1–3.3)			M = 0.5 (0–3.3)	M = 1.8 (1–3.3)
	30 days after administration of the second dose	27	100	3.1^a	3.1^b	28	96.4	2.4^c	2.5^d
				M = 3.3 (1.1–3.3)	M = 3.3 (1.1–3.3)			M = 2.3 (0–3.3)	M = 2.3 (1.4–3.3)

CS: conventional schedule; RS: rapid schedule; N: total number of subjects in the groups; GMTA: geometric mean titer of TBEV-neutralizing antibodies; M: median; ( ): nAbs titer range; ^a,b,c,ddifference between the nAbs titers measured on day 14 and those measured on day 30 after immunization according to rapid schedule (MWT).